Beyond Castration-Defining Future Directions in the Hormonal Treatment of Prostate Cancer

Hormones and Cancer

Volumn 3, Issue 1-2, 2012, Pages 3-13

  Niraula, Saroj ^a   Chi, Kim ^b   Joshua, Anthony Michael ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Abiraterone; MDV3100; Prostate cancer; Testosterone

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; ABIRATERONE; ANDROGEN; ANTINEOPLASTIC AGENT; ARN 509; ASP 9521; AZD 3514; BICALUTAMIDE; BKM 120; CUSTIRSEN; CYTOCHROME P450 17; DENOSUMAB; DOCETAXEL; DUTASTERIDE; EPI 001; EZN 4176; FLUTAMIDE; GALETERONE; GANETESPIB; GOSERELIN; LEUPRORELIN; NILUTAMIDE; ODM 201; OGX 427; ORTERONEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; ANDROGEN THERAPY; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DNA BINDING; DOSE RESPONSE; DRUG APPROVAL; DRUG BINDING; DRUG CYTOTOXICITY; DRUG EXPOSURE; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INDUCTION; FOLLOW UP; HUMAN; METASTASIS; MONOTHERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN FUNCTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TREATMENT RESPONSE;

ANDROSTADIENES; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; STEROID 17-ALPHA-HYDROXYLASE;

EID: 84856652439     PISSN: 18688497     EISSN: 18688500     Source Type: Journal    
DOI: 10.1007/s12672-011-0096-0     Document Type: Review

References (64)

1. Scher HI, Sawyers CL (2005) Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23(32): 8253-8261.
2. Chen Y, Sawyers CL, Scher HI (2008) Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 8(4): 440-448.
3. Pienta KJ, Bradley D (2006) Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 12(6): 1665-1671.
4. Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev Cancer 1(1): 34-45.
5. Mostaghel EA, Nelson PS (2008) Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications. Best Pract Res Clin Endocrinol Metab 22(2): 243-258.
6. Mohler JL et al (2004) The androgen axis in recurrent prostate cancer. Clin Cancer Res 10(2): 440-448.
7. Attard G, Richards J, de Bono JS (2011) New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res 17(7): 1649-1657.
8. Hu R, Denmeade SR, Luo J (2010) Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer. Expert Rev Endocrinol Metab 5(5): 753-764.
9. Visakorpi T et al (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9(4): 401-406.
10. Mellado B et al (2009) Molecular biology of androgen-independent prostate cancer: the role of the androgen receptor pathway. Clin Transl Oncol 11(1): 5-10.
11. Taylor BS et al (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18(1): 11-22.
12. Ryan CJ et al (2010) Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 28(9): 1481-1488.
13. Attard G et al (2008) Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26(28): 4563-4571.
14. Danila DC et al (2010) Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 28(9): 1496-1501.
15. Ryan CJ et al (2011) Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res 17(14): 4854-4861.
16. de Bono JS et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21): 1995-2005.
17. Chen H et al (2003) Can older cancer patients tolerate chemotherapy? A prospective pilot study. Cancer 97(4): 1107-1114.
18. Matsunaga N et al (2004) C(17, 20)-lyase inhibitors. Part 2: design, synthesis and structure-activity relationships of (2-naphthylmethyl)-1H-imidazoles as novel C(17, 20)-lyase inhibitors. Bioorg Med Chem 12(16): 4313-4336.
19. Dreicer R, Agus DB, MacVicar GR, Wang J, MacLean D, Stadler WM (2010) Safety, pharmacokinectics, and efficacy of TAK-700 in metastatic castration-resistant prostate cancer: a phase I/II open-label study. In American Society of Clinical Oncology Genitourinary Symposium: San Francisco.
20. Scher HI et al (2010) Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 375(9724): 1437-1446.
21. Higano CS, Beer TM, Taplin M, Efstathiou E, Anand A, Hirmand M, Flesher M, Scher HI (2011) Antitumor activity of MDV3100 in pre and post-docetaxel advanced prostate cancer: long-term follow-up of a phase I/II study. In 2011 Genitourinary Cancers Symposium, American Society of Clinical Oncology: Orlando, Florida.
22. Swanson HI et al (2010) Targeting drug-metabolizing enzymes for effective chemoprevention and chemotherapy. Drug Metab Dispos 38(4): 539-544.
23. Cai C et al (2011) Intratumoral de novo steroid synthesis activates androgen receptor in castration resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res 71: 6503.
24. Kuruma H, Matsumoto H, Zoubeidi A, Thomas C, Lamoureux F, Gleave M (2011) Use of MDV3100 to establish androgen-receptor antagonist resistant LNCaP cells for modelling castrate-resistant progression. American Association of Cancer Research, Orlando.
25. Guo Z, Qiu Y (2011) A new trick of an old molecule: androgen receptor splice variants taking the stage?! Int J Biol Sci 7(6): 815-822.
26. Haile S, Sadar MD (2011) Androgen receptor and its splice variants in prostate cancer. Cell Mol Life Sci 68(24): 3971-3981. doi: 10. 1007/500018-011-0766-7.
27. Hu R, Isaacs WB, Luo J (2011) A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities. Prostate 71(15): 1656-1667.
28. Watson PA et al (2010) Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A 107(39): 16759-16765.
29. Carver BS et al (2011) Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell 19(5): 575-586.
30. Mulholland DJ et al (2011) Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 19(6): 792-804.
31. Sadar MD (2011) Small molecule inhibitors targeting the "Achilles' heel" of androgen receptor activity. Cancer Res 71(4): 1208-1213.
32. Andersen RJ et al (2010) Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell 17(6): 535-546.
33. Quayle SN et al (2007) Androgen receptor decoy molecules block the growth of prostate cancer. Proc Natl Acad Sci U S A 104(4): 1331-1336.
34. Jenster G et al (1991) Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol 5(10): 1396-1404.
35. Sadar MD et al (2008) Sintokamides A to E, chlorinated peptides from the sponge Dysidea sp. that inhibit transactivation of the N-terminus of the androgen receptor in prostate cancer cells. Org Lett 10(21): 4947-4950.
36. Fowler JE Jr, Whitmore WF Jr (1982) Considerations for the use of testosterone with systemic chemotherapy in prostatic cancer. Cancer 49(7): 1373-1377.
37. Rathkopf D et al (2008) Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. J Clin Oncol 26(18): 2959-2965.
38. Manni A et al (1988) Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. J Clin Oncol 6(9): 1456-1466.
39. Boccardo F et al (2011) Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen receptor-positive breast cancer patients. Very late results of the 'gruppo di ricerca per la chemio-ormonoterapia adiuvante (GROCTA)' 01-Trial in early breast cancer. Breast Cancer Res Treat 126(3): 653-661.
40. Albain KS et al (2009) Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 374(9707): 2055-2063.
41. Darshan MS et al (2011) Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res 71(18): 6019-6029.
42. Gan L et al (2009) Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res 69(21): 8386-8394.
43. Tzelepi V et al (2011) Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol 29(18): 2574-2581.
44. Mellado B et al (2009) Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer. Br J Cancer 101(8): 1248-1252.
45. Ryan CJ, Small EJ (2003) Role of secondary hormonal therapy in the management of recurrent prostate cancer. Urology 62(Suppl 1): 87-94.
46. Smith MR et al (2011) Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer 117(10): 2077-2085.
47. Bolla M et al (2009) Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360(24): 2516-2527.
48. Zagars GK, Pollack A, von Eschenbach AC (1997) Serum testosterone-a significant determinant of metastatic relapse for irradiated localized prostate cancer. Urology 49(3): 327-334.
49. Roach M 3rd et al (2010) Baseline serum testosterone in men treated with androgen deprivation therapy and radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 78(5): 1314-1322.
50. Taira AV et al (2011) Serum testosterone kinetics after brachytherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. doi: 10. 1016/j. ijrobp. 2011. 01. 027.
51. Mostaghel EA et al (2007) Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 67(10): 5033-5041.
52. Milosevic M et al (2007) Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response. Cancer Res 67(13): 6022-6025.
53. Laverdiere J et al (1997) Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 37(2): 247-252.
54. Hanks GE et al (2003) Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21(21): 3972-3978.
55. Denham JW et al (2008) Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96. 01 randomised controlled trial. Lancet Oncol 9(11): 1058-1068.
56. Horwitz EM et al (2008) Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 26(15): 2497-2504.
57. Aus G et al (2002) Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int 90(6): 561-566.
58. Klotz LH et al (2003) Long-term follow up of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 170(3): 791-794.
59. Williams SB et al (2011) Utilization and expense of adjuvant cancer therapies following radical prostatectomy. Cancer 117(32): 4846-4854.
60. Siddiqui SA et al (2011) Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer. BJU Int 107(3): 383-388.
61. Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD (2006) Neoadjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 4: CD006019.
62. Efstathiou E, Titus M, Tsavachidou D, Tzelepi V, Wen S, Hoang A, Molina A, Chieffo N, Smith LA, Smith MK, Troncoso P, Logothetis CJ (2011) Characterization of castrate resistant prostate cancer treated with abiraterone acetate and prednisone. American Association for Cancer Research, Orlando.
63. Attard G et al (2009) Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 27(23): 3742-3748.
64. Efstathiou E, Tu S, Aparicio A, Hoang A, Wen S, Troncoso P, Smith LA, Chieffo N, Molina A, Logothetis C (2010) Use of "intracrine androgen signaling signature" to predict benefit from abiraterone acetate (AA) in patients with castrate-resistant prostate cancer (CRPC), in 2010 ASCO Annual Meeting. American Society of Clinical Oncology, Chicago.